Additional funding opportunities
Research Funding Opportunities
Grants Awarded for Health Sciences Research
Title |
Type | $ Amount | Activity | Investigator | Unit | Sponsor | Date |
|---|---|---|---|---|---|---|---|
| A Prospective Multicenter Randomized Controlled Clinical Study to Investigate the Safety and Effectiveness of the RECELL System Combined with Meshed Autograft for Reduction of Donor Skin Harvesting | Contract | $229,008.88 | Clinical Trial | Lourdes Castanon | Surgery | Avita Medical Americas, LLC | 01/2021 |
| A Prospective, Multi-center, Single Arm Study to Obtain “Real World” Clinical Data and Characterize the Acute and Long-term Performance of the Micrusframe and Galaxy Coils for the Endovascular Treatment | Contract | $109,963.64 | Clinical Trial | Mohammad El-ghanem | Neurology | Cerenovus | 03/2021 |
| A Prospective, Multicenter, Randomized, Controlled Pivotal Trial to Evaluate the Safety and Effectiveness of Transcatheter Mitral Valve Repair with the Edwards PASCAL Transcatheter ...... | Contract | $141,792.00 | Clinical Trial | Ashish Pershad | COM Phx Internal Medicine | Edwards Lifesciences LLC | 06/2020 |
| A Prospective, Randomized, Open-Label, Comparative Study to Assess the Efficacy, Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI) and Best Available Therapy for the Treatment of Serious... | Contract | $240,575.50 | Clinical Trial | Bellal Joseph | Surgery | Parexel International Corporation | 03/2020 |
| A Randomized Clinical Trial of Andexanet Alfa in Acute Intracranial Hemorrhage in Patients Receiving an Oral Factor Xa Inhibitor | Contract | $535,294.50 | Clinical Trial | Bellal Joseph | Surgery | Portola Pharmaceuticals, Inc. | 03/2021 |
| A Randomized Controlled Trial to Improve Mother-Infant Synchrony Among Women with Childhood Adversity | Grant | $2,437,784.00 | Research | Aleeca Bell | College of Nursing | National Institute of Nursing Research | 09/2020 |
| A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Enzastaurin Plus R-CHOP Versus R-CHOP in Treatment-Naive Subjects with High-Risk Diffuse Large B-Cell Lymphoma Who Possess the Novel.. | Contract | $327,830.00 | Clinical Trial | Abhijeet Kumar | Cancer Center Division | Covance, Incorporated | 01/2020 |
| A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First- Line Treatment of BRCA Non-Mutated Advanced... | Contract | $100,897.00 | Clinical Trial | Setsuko Chambers | Cancer Center Division | GOG Foundation, Inc. | 08/2020 |
| A Randomized, Double Blind, Parallel-Group, Placebo Controlled Study to Evaluate the Efficacy and Safety of IBP-9414 in Premature Infants 500-1500g Birth Weight in the Prevention of Necrotizing... | Contract | $1,019,895.00 | Clinical Trial | Ranjit Kylathu | Pediatrics | Infant Bacterial Therapeutics AB (SWEDEN) | 01/2021 |
| A Randomized, Double-blind Dose-ranging, Placebo-controlled Phase 2a Evaluation of the Safety, Tolerability and Pharmacokinetics of PLN-74809 in Participants With Idiopathic Pulmonary Fibrosis (Ipf).. | Contract | $119,271.00 | Clinical Trial | Marilyn Glassberg Csete | COM Phx Internal Medicine | Pliant Therapeutics, Inc. | 04/2021 |
| A Randomized, Double-Blind Placebo-Controlled, Phase 3 Study of Debio 1143 in Combination with Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Patients with | Contract | $840,502.68 | Clinical Trial | Ricklie Julian | Cancer Center Division | Syneos Health | 01/2021 |
| A Randomized, Double-Blind, Parallel Group, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of Once Weekly Subcutaneous Injections of a Sustained-Release VIP Analogue, PB1046, in Adult | Contract | $345,225.92 | Clinical Trial | Franz Rischard | Medicine | PhaseBio Pharmaceuticals, Inc. | 01/2021 |
| A Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of Pulsed, Inhaled Nitric Oxide (iNO) Versus Placebo in Subjects With Mild or Moderate Coronavirus Disease (Covid | Contract | $503,260.68 | Clinical Trial | Jarrod Mosier | Dept of Emergency Medicine | Pharmaceutical Research Associates | 08/2020 |
| A Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy and Safety of Pulsed, Inhaled Nitric Oxide (iNO) Versus Placebo in Subjects with Mild to Moderate Coronavirus Disease... | Contract | $502,490.72 | Clinical Trial | Thomas Ardiles | COM Phx Internal Medicine | Pharmaceutical Research Associates | 07/2020 |
| A Randomized, Double-blind, Placebo-Controlled Clinical Trial of Fluconazole as Early Empiric Treatment of Coccidioidomycosis Pneumonia (Valley Fever) in Adults Presenting with Community Acquired ... | Contract | $593,373.00 | Other Sponsored Activity | John Galgiani | Valley Fever Ctr for Excellnc | Duke University | 03/2021 |
| A Randomized, Double-blind, Placebo-controlled Clinical Trial of Fluconazole as Early Empiric Treatment of Coccidioidomycosis Pneumonia (Valley Fever) in Adults Presenting with Community Acquired... | Contract | $593,373.00 | Clinical Trial | John Galgiani | Valley Fever Ctr for Excellnc | Duke University | 06/2020 |
| A Randomized, Double-Blind, Placebo-Controlled, Active Comparator Phase 2/3 study of Tucatinib in Combination with Trastuzumab, Ramucirumab, and Paclitaxel in Subjects with Previously Treated, Locally | Contract | $453,804.20 | Clinical Trial | Aaron Scott | Cancer Center Division | Seagen Inc. | 01/2021 |
| A Randomized, Double-blind, Placebo-controlled, Clinical Trial of LY3127804 in Patients who are Hospitalized with Pneumonia and Presumed or Confirmed COVID-19 | Contract | $1,181,507.00 | Clinical Trial | Jarrod Mosier | Dept of Emergency Medicine | Target Health, LLC | 10/2020 |
| A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Patients with COVID-19 Pneumonia | Contract | $3,236,387.50 | Clinical Trial | Sachin Chaudhary | Medicine | Syneos Health | 06/2020 |
| A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 as Adjunctive Therapy in Focal-onset Epilepsy, with an Open Label... | Contract | $107,762.52 | Clinical Trial | David Labiner | Neurology | NCGS Incorporated | 03/2020 |
| A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of LY3819253 in Participants with Mild to Moderate COVID-19 Illness | Contract | $1,003,039.00 | Clinical Trial | Jarrod Mosier | Dept of Emergency Medicine | Eli Lilly and Company | 09/2020 |
| A Randomized, Double-Blind, Placebo-controlled, Single-ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of JK07 in Subjects with Heart Failure with Reduced Ejection Fra... | Contract | $606,162.95 | Clinical Trial | Nancy Sweitzer | Sarver Heart Center | Salubris Biotherapeutics | 01/2021 |
| A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination with Ipilimumab Compared to Sorafenib or Lenvatinib as First-Line Treatment in Participants with Advanced Hepatocellular Carcinoma | Contract | $242,423.80 | Clinical Trial | Rachna Shroff | Cancer Center Division | Syneos Health | 06/2021 |
| A Randomized, Phase 2 Study of Stereotactic Body Radiation Therapy (SBRT) in Combination with GC4711 in the Treatment of Unresectable or Borderline Resectable, Nonmetastatic Pancreatic Cancer | Contract | $239,544.80 | Clinical Trial | Uma Goyal | Cancer Center Division | Galera Therapeutics, LLC | 05/2021 |
| A Randomized, Phase 3 Study of Eryaspase in Combination with Chemotherapy versus Chemotherapy Alone as Second-Line Treatment in Patients with Pancreatic Adenocarcinoma (TRYbeCA-1 - TRial of ErYaspase | Contract | $664,687.53 | Clinical Trial | Hani Babiker | Cancer Center Division | PPD Investigator Services, LLC. | 05/2020 |